Octanine (human plasma derived coagulation factor IX) / Octapharma - LARVOL DELTA

[VIRTUAL] Prospective, Open-label, Multicentre Phase II Study (PeKaFIX) to Evaluate the Pharmacokinetic Parameters of a Plasma Derived Factor IX Concentrate and Build a Pharmacokinetic Bayesian Model (ISTH 2021) - "Conclusions : OCTANINE® has a terminal half-life of 35 hours after a single administration. The FIX model enables sparse sampling data to be used to individualise OCTANINE® prophylaxis and suggests that some patients could be treated with less frequent injections to maintain a trough level above 1%."

Clinical • P2 data • PK/PD data • Hematological Disorders • Hemophilia • Rare Diseases

Octapharma's ongoing dedication to improving the lives of people with haemophilia and von Willebrand disease to be showcased at the ISTH 2021 Congress (PRNewswire) - "Octapharma announced today that new clinical and scientific findings encompassing their Haematology portfolio, including Nuwiq®, wilate®, octanate® and octanine®F, will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on July 17–21, 2021."

Clinical data • Hemophilia

Protein aggregates in plasma-derived factor IX (pdFIX) concentrates support platelet activation and microparticle formation in vitro (WFH 2016) - "While we found in BeneFIX only sporadically small singular particles, pdFIX concentrates contained a lot more particles. Size distribution was different in different pdFIX concentrates. PdFIX supported platelet activation and microparticle formation induced by low concentrations of agonists, while rFIX did not. Removal of protein aggregates from pdFIX prevented the activation effect on platelets, without having and influence on FIX activity."

Biomarker • Hemophilia